BB Biotech AG (CH:BION)
:BION
Top Page
BB Biotech
(BION)
Select Model
Select Model
Rating:68Neutral
Price Target:
CHF54.00
▲(20.13% Upside)
Action:ReiteratedDate:12/30/25
The score is driven primarily by improved 2024 financial performance (profitability, cash flow, and low leverage) but tempered by pronounced historical volatility. Technicals add support via an uptrend and positive MACD, while valuation is reasonable with a ~3.95% dividend yield.
Positive Factors
Sector-focused investment vehicle
A dedicated biotech investment vehicle concentrates domain expertise and research resources on one sector, enabling informed stock selection and thematic exposure. Over months this focused approach supports the potential for outperformance through active allocation to innovation and catalyst-driven winners.
Negative Factors
High historical volatility of results
Marked multi-year volatility shows portfolio valuations and operating metrics swing widely with biotech cycles. This structural volatility complicates forecasting, may force realizations at unfavorable times, and weakens predictability of NAV and income across 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Sector-focused investment vehicle
A dedicated biotech investment vehicle concentrates domain expertise and research resources on one sector, enabling informed stock selection and thematic exposure. Over months this focused approach supports the potential for outperformance through active allocation to innovation and catalyst-driven winners.
Read all positive factors
BB Biotech (BION) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.47B
Dividend Yield3.95%
Average Volume (3M)98.23K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth83.74%
EPS Growth31.82%
CountryCH
Employees10
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)8.55
Shares Outstanding55,400,000
10 Day Avg. Volume119,513
30 Day Avg. Volume98,228
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)0.85
Price to Sales (P/S)17.44
P/FCF Ratio6.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF66.00Price Target Upside46.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.1
Revenue Forecast (FY)N/A
BB Biotech Business Overview & Revenue Model
Company Description
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based...
How the Company Makes Money
BB Biotech makes money through its investment activities in the biotechnology sector. The company generates revenue primarily from the appreciation of its investments in biotechnology companies. This includes capital gains realized from selling sh...
BB Biotech Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -176.15M | 111.63M | 35.00K | 4.00K | -396.22M | 699.23M |
| Gross Profit | -176.15M | 111.63M | 35.00K | 4.00K | -396.22M | 699.23M |
| EBITDA | 0.00 | 80.24M | -201.26M | -357.29M | -402.79M | 691.25M |
| Net Income | -438.69M | 75.90M | -206.61M | -357.81M | -404.81M | 691.17M |
Balance Sheet | ||||||
| Total Assets | 1.84B | 2.41B | 2.64B | 3.05B | 3.64B | 3.96B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16M | 2.41B | 2.64B | 3.05B | 3.64B | 3.96B |
| Total Debt | 0.00 | 117.50M | 304.90M | 363.00M | 355.00M | 63.00M |
| Total Liabilities | 2.43M | 121.11M | 313.94M | 367.25M | 355.00M | 63.00M |
| Stockholders Equity | 1.84B | 2.29B | 2.32B | 2.69B | 3.28B | 3.89B |
Cash Flow | ||||||
| Free Cash Flow | 435.73M | 304.56M | 218.28M | -357.81M | -94.79M | 262.45M |
| Operating Cash Flow | 435.73M | 304.56M | 218.28M | -357.81M | -94.79M | 262.45M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 588.94M | 0.00 | 0.00 |
| Financing Cash Flow | -427.20M | -305.20M | -220.21M | -233.27M | 91.77M | -284.48M |
BB Biotech Technical Analysis
Positive
44.95
Price Trends
43.85
Positive
43.56
Positive
38.29
Positive
Market Momentum
0.25
Negative
57.41
Neutral
76.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BION, the sentiment is Positive. The current price of 44.95 is above the 20-day moving average (MA) of 43.59, above the 50-day MA of 43.85, and above the 200-day MA of 38.29, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 57.41 is Neutral, neither overbought nor oversold. The STOCH value of 76.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BION.
BB Biotech Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF664.04M | 16.63 | ― | ― | 58.51% | ― | |
68 Neutral | CHF2.47B | ― | -20.74% | 3.95% | 83.74% | 31.82% | |
56 Neutral | CHF959.35M | 498.59 | -7.82% | ― | 104.01% | 33.25% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | CHF312.92M | -38.37 | ― | ― | 744.64% | ― | |
45 Neutral | CHF136.47M | -2.50 | -51.05% | ― | -100.00% | 14.45% | |
45 Neutral | CHF891.34M | -8.17 | ― | ― | 229.23% | 63.47% |
* General Sector Average
CH:BION
BB Biotech
44.95
19.81
78.81%
CH:MOLN
Molecular Partners AG
3.38
0.17
5.30%
CH:BSLN
Basilea Pharmaceutica
54.50
13.45
32.76%
CH:IDIA
Idorsia Ltd
3.52
2.47
233.71%
CH:KURN
Kuros Biosciences
24.44
5.60
29.72%
CH:NWRN
Newron Pharmaceuticals SpA
15.04
8.55
131.74%
BB Biotech Corporate Events
BB Biotech Forecasts Surge in 2025 Profit to CHF 578 Million
Jan 23, 2026
BB Biotech AG expects to report an unaudited profit of around CHF 578 million for the 2025 financial year, a sharp increase from CHF 76 million a year earlier, reflecting strong share price performance among the biotech companies in its portfolio....
BB Biotech posts strong 2025 rebound and lifts dividend after biotech outperformance
Jan 23, 2026
BB Biotech AG reported a sharp turnaround in 2025 with a preliminary net profit of CHF 578 million versus CHF 76 million a year earlier, driven by a strong share price total return of up to 53.7% in USD terms and net asset value gains that outpace...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.